Cure My Disease

Don't miss your cure!

 Log in / Sign up

Chemo-Free combo for lymphoma shows promise in early trial

NCT ID NCT04268277

Terminated Disease control Sponsor: University of Ulm Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested a combination of two drugs, pembrolizumab (Keytruda) and rituximab (Truxima), in 22 people with marginal zone lymphoma, a type of blood cancer. The goal was to see if this chemotherapy-free approach could control the disease with fewer side effects than standard chemo. The study was terminated early, so the full results are not yet clear.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Pembrolizumab (Keytruda) and Rituximab (Truxima)
What this could lead to
If successful, this could provide a chemotherapy-free treatment option for marginal zone lymphoma, potentially reducing side effects while controlling the disease.
What could go wrong
The trial was terminated early with only 22 participants, so results are limited. It is a small phase 2 study, and the combination may not be as effective as standard chemo or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Lymphoma, B-Cell, Marginal Zone marginal zone lymphoma neoplasm Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MARGINAL ZONE LYMPHOMA

Contacts and locations

Locations

  • Brüderkrankenhaus St. Josef, Klinik für Hämatologie und Onkologie

    Paderborn, 33098, Germany

  • Charité Universitätsmedizin Berlin; Hämatologie - Onkologie - Tumorimmunologie

    Berlin, 12200, Germany

  • Gemeinschaftspraxis Dr. med. Johannes Mohm, Dr. med. Gabriele Prange-Krex

    Dresden, 01307, Germany

  • Gemeinschaftspraxis für Hämatologie und Onkologie

    Münster, 48149, Germany

  • Kliniken Maria Hilf GmbH; Klinik für Hämatologie, Onkologie und Gastroenterologie

    Mönchengladbach, 41063, Germany

  • Klinikum Chemnitz gGmbH, Klinik für Innere Medizin III

    Chemnitz, 09116, Germany

  • Klinikum Oldenburg AöR, Universitätsklinik für Innere Medizin, Onkologie und Hämatologie

    Oldenburg, 26133, Germany

  • Klinikum Passau, II. Medizinische Klinik - Hämatologie, Onkologie und Palliativmedizin

    Passau, 94032, Germany

  • Klinikum rechts der Isar der TU München, Klinik und Poliklinik für Innere Medizin III

    München, 81675, Germany

  • RoMed Klinikum Rosenheim, Med. Klinik II / OTK

    Rosenheim, 83002, Germany

  • Robert-Bosch-Krankenhaus; Hämatologie, Onkologie und Palliativmedizin

    Stuttgart, 70376, Germany

  • Universitätsklinikum Ulm; Klinik für Innere Medizin Innere Medizin III

    Ulm, Baden-Wurttemberg, 89081, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.